Inovio Pharmaceuticals Inc. (INO): Price and Financial Metrics
INO Price/Volume Stats
| Current price | $10.50 | 52-week high | $14.75 |
| Prev. close | $10.02 | 52-week low | $3.89 |
| Day low | $9.95 | Volume | 98,783 |
| Day high | $10.82 | Avg. volume | 520,380 |
| 50-day MA | $10.29 | Dividend yield | N/A |
| 200-day MA | $6.77 | Market Cap | 245.39M |
INO Stock Price Chart Interactive Chart >
Inovio Pharmaceuticals Inc. (INO) Company Bio
Inovio Pharmaceuticals Inc is a clinical stage biopharmaceutical company. It develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. Inovio leverages its optimized plasmid design and delivery technology to develop DNA medicines to potentially treat and prevent diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. The company has more than 2,000 patients receiving Inovio DNA medicines in more than 7,000 clinical trial applications. Inovio’s corporate headquarters is in Plymouth Meeting, Pennsylvania with research & development and manufacturing facilities in San Diego, California. Dr. J. Joseph Kim serves as the company’s President and Chief Executive Officer.
Latest INO News From Around the Web
Below are the latest news stories about INOVIO PHARMACEUTICALS INC that investors may wish to consider to help them evaluate INO as an investment opportunity.
The 3 Most Undervalued Biotech Stocks to Buy: November 2023Given the undervalued biotech industry, these three undervalued biotech stocks to buy are ripe purchase targets for high-potential profits. |
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q3 2023 Earnings Call TranscriptInovio Pharmaceuticals, Inc. (NASDAQ:INO) Q3 2023 Earnings Call Transcript November 9, 2023 Inovio Pharmaceuticals, Inc. reports earnings inline with expectations. Reported EPS is $-0.13 EPS, expectations were $-0.13. Operator: Good afternoon, ladies and gentlemen and welcome to the Inovio Third Quarter 2023 Financial Results Conference Call. At this time all lines are in a listen-only […] |
Inovio Pharmaceuticals (INO) Q3 2023 Earnings Call TranscriptGood afternoon, and thank you for joining the Inovio 2023 third quarter conference call. Joining me on today's call are Dr. Jackie Shea, president and CEO; Dr. Michael Sumner, chief medical officer; Mr. |
INOVIO Reports Third Quarter 2023 Financial Results and Operational HighlightsINOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results and operational highlights for the third quarter ended September 30, 2023. |
INOVIO Reports Inducement Grants Under Inducement PlanINOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan"). |
INO Price Returns
| 1-mo | -9.64% |
| 3-mo | 51.52% |
| 6-mo | 127.51% |
| 1-year | 1.60% |
| 3-year | -87.23% |
| 5-year | -77.21% |
| YTD | 71.57% |
| 2023 | -67.31% |
| 2022 | -68.74% |
| 2021 | -43.62% |
| 2020 | 168.18% |
| 2019 | -17.50% |
Continue Researching INO
Want to see what other sources are saying about Inovio Pharmaceuticals Inc's financials and stock price? Try the links below:Inovio Pharmaceuticals Inc (INO) Stock Price | Nasdaq
Inovio Pharmaceuticals Inc (INO) Stock Quote, History and News - Yahoo Finance
Inovio Pharmaceuticals Inc (INO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...